Portland GIST Day of Learning – Christopher Corless, MD
GIST Pathology and Mutational Testing Update
Informative Webcast Sheds Light on Mutational Analysis
Dr. Chris Corless In August, the LRG Webcast Series presented “Mutational Analysis of GISTs: How, When and Why.” Dr. Christopher Corless of Oregon Health and Science University (OHSU) presented the hour- long [...]
Mutational Analysis of GISTs: How, When, and Why
Please join us for an afternoon of learning about the importance of and the science behind mutational testing with pathologist and GIST specialist, Dr. Christopher Corless of Portland's Oregon Health and Science University. This [...]
2013 LRG Research Team Progress Report
Accomplishments—Recent Progress: 1. Using mouse models, successfully attacked GIST with antibodies, essentially telling immune system to eat the cancer cells.
How ‘Next Generation’ DNA sequencing is changing the landscape of GIST research and diagnosis
During the past dozen years gastrointestinal stromal tumors have emerged from oncologic obscurity and reached center-stage in the development of targeted therapies for solid tumors. Tyrosine kinase inhibitors (TKIs) like imatinib, sunitinib, and more recently regorafenib, have proven effective in suppressing the growth of metastatic GIST, allowing patients to live far longer than during the previous era of ineffective chemotherapy.